ABRx Panel  by Diatherix

ABRx

Antibiotic Resistance Panel

A unique molecular solution
to combat the challenges
of antibiotic resistances

Identifies 17 genes responsible for resistance
to β-lactams, macrolides, and fluoroquinolones

See the genes and classes covered:

Antibiotic Class Panel Target Antibiotic Class Avoidance
β-Lactam CTX-M Group 1 cephalosporins, penicillins, aztreonam
CTX-M Group 2 cephalosporins, penicillins, aztreonam
CTX-M Group 8/25 cephalosporins, penicillins, aztreonam
CTX-M Group 9 cephalosporins, penicillins, aztreonam
KPC carbapenems, cephalosporins, penicillins, β-lactamase inhibitors, aztreonam
IMP carbapenems, cephalosporins, penicillins, β-lactamase inhibitors
VIM carbapenems, cephalosporins, penicillins, β-lactamase inhibitors
NDM carbapenems, cephalosporins, penicillins, β-lactamase inhibitors
FOX cephalosporins, penicillins, β-lactamase inhibitors
OXA-1 cloxacillin, oxacillin, penicillins
OXA-48 carbapenems, extended spectrum cephalosporins, penicillins, β-lactamase inhibitors
PER extended spectrum cephalosporins, penicillins, aztreonam
VEB extended spectrum cephalosporins, penicillins, aztreonam
GES carbapenems, cephamycins, extended spectrum cephalosporins, penicillins
Macrolide ermB macrolides (erythromycin, clindamycin, azithromycin)
Fluoroquinolone qnrA fluoroquinolones (ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin)
qnrS fluoroquinolones (ciprofloxacin, gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin)

Benefits of ABRx

Broad.

Seventeen
inclusive targets
within multiple classes.

The most comprehensive genetic resistance diagnostic on the market. The ABRx Panel identifies 17 genes responsible for resistances to β-lactams, macrolides, and fluoroquinolones.

Direct.

Clear cut
molecular details
from the infectious process.

Testing directly from clinical specimen rather than culture isolate reveals genes present in the in vivo infectious environment that can be missed otherwise.
(May be performed on culture isolates also.)

Impact.

One day results
make antimicrobial
stewardship actionable.

With One Day Results, the ABRx Panel can make an impact to change or reduce therapy, leading to improved outcomes and reduced costs. The ABRx Panel is particularly impactful for antimicrobial stewardship.

Technical Resources

Strategies for Detection

TECHNICAL BULLETIN

Phenotypic Versus Genotypic Antimicrobial Resistance Profiles: Strategies for Detection of Antimicrobial Resistance
(see the PDF)

Antibiotic Gene Resistance Screening

TECHNICAL BULLETIN

Antibiotic Gene Resistance Screening in the Healthcare Environment: When and Where
(see the PDF)

ABRx Technical Bulletin

TECHNICAL BULLETIN

Diatherix Laboratories has developed the ABRx Antibiotic Resistance Panel that tests for seventeen antibiotic resistance genes responsible for resistance to three major classes of antibiotics routinely prescribed…
(see the PDF)

 

Inclusivity and Specificity

POSTER

167 characterized clinical isolates were tested for inclusivity with 100% concordance to reported phenotypic antibiotic resistance profiles, independent PCR, and sequencing tests.
(see the poster)

Comparison to Phenotypic Methods

POSTER

Our findings indicate that the accuracy of the ABRx Panel is comparable to the Kirby-Bauer and the microbroth dilution methods in predicting antibiotic class resistance phenotypes and is an innovative and rapid alternative to conventional AST methods.
(see the poster)

ABRx Panel Overview

INFO SHEET

The ABRx Panel is built on a nanofluidic real-time PCR OpenArray® platform which allows spatial assay multiplexing and simultaneous detection of resistance genes directly from a clinical specimen.
(see the PDF)

Request Information

Interested In: *
  • Developed by Diatherix

    Diatherix Laboratories developed the ABRx™ Antibiotic Resistance Panel to provide a powerful diagnostic tool to the market. The panel was designed in collaboration with Thermo Fisher Scientific.

    Visit Diatherix.com

    to learn more about Diatherix